Navigation Links
PARI Nebulizer & Compressor Used Exclusively in Inspire's Phase 3 CF Trial
Date:3/10/2008

MIDLOTHIAN, Va., March 10 /PRNewswire/ -- PARI's LC STAR nebulizer and PRONEB Ultra II compressor are the exclusive delivery devices for Inspire Pharmaceuticals' (Nasdaq: ISPH) second Phase 3 clinical trial for a potential new cystic fibrosis treatment. PARI reusable nebulizers are considered the gold standard for clinical trials and are recommended in commercial sales including AstraZeneca's Pulmicort Respules, Sepracor's Xopenex and Brovana, Novartis' TOBI, Genentech's Pulmozyme, and DEY LP's Accuneb, Duoneb, and Perforomist.

"PARI has a strong track record of reliable and efficient, reproducible drug delivery, so it only makes sense that so many pharmaceutical companies look to PARI when developing new medications," said Lisa Cambridge, director of Clinical Development at PARI Respiratory Equipment. "Our LC STAR is a fine particle nebulizer that enables delivery of aerosols to the smaller airways of the lungs -- beneficial for successful respiratory therapies."

Known as TIGER-2, Inspire's second pivotal Phase 3 clinical trial with denufosol tetrasodium inhalation solution is beginning enrollment in the U.S. and Canada with patients age 5 years and older. The use of standard CF maintenance therapies is permitted during the trial, and additional information is available at http://www.inspirepharm.com.

The combination of PARI's LC STAR nebulizer and PRONEB Ultra II compressor provides for a quick treatment with high efficiency and minimal medication waste.

It is hoped that denufosol could be the first early intervention therapy available to CF patients that affects an early step in the progression of the disease. Denufosol for the treatment of cystic fibro
'/>"/>

SOURCE PARI Respiratory Equipment, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" ... today announced financial results for its first quarter ended ... months ended December 31, 2014, revenue was $1,336,685. Operating ... $229,820 or $0.02 per share.  Covalon,s ... am very pleased with the significant progress we have ...
(Date:2/27/2015)... 2015 ... kongestive Herzinsuffizienz (CHF) in seiner ersten klinischen ...   Die israelische Firma ... für Patienten mit kongestiver Herzinsuffizienz (CHF) entwickelt ... Finanzierungsvorhaben über 5 Mio. USD abgeschlossen hat. ...
(Date:2/27/2015)... , Feb. 27, 2015  Chiasma, Inc., a ... product for the orphan condition acromegaly, today announced the ... Participants in the financing included new investors Rock Springs ... public investment fund, as well as existing investors MPM ... ARCH Venture Partners. Chiasma intends to ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... recent study conducted by oculoplastic surgeon Charles Soparkar, ... a patent-pending formulation of zinc and phytase (trademarked ... oral administration for 4 days prior to a ... duration in 41 of 44 patients tested (93%). ...
... ABT ) announced today it has received approval from the U.S. ... e HBV assay for measuring viral load or the amount of ... first and only approved test capable of automating HBV viral load ... Abbott RealTi m e HBV assay, based on real-time PCR (polymerase ...
Cached Medicine Technology:Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results 2Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment 2Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment 3Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment 4
(Date:2/28/2015)... 28, 2015 The Heart Fit Clinic ... distributor of the machine. The Heart Fit Clinic is ... like a franchise model. The goal is to scale ... heart disease. To buy External Counterpulsation machines ... help individuals through this process and achieve the desired ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate ... provide business consulting services in addition to a variety ... and succession planning. Company finances are a complicated matter ... top of this, complex Canadian tax laws can make ... a result, Mew and Company works to advise their ...
(Date:2/28/2015)... A study out of the University ... procedure for the treatment of a hereditary ocular condition ... Authored by Dr. Robert MacLaren, professor of ophthalmology at ... Medical Journal on January 16, 2014 , the study ... disorder that mostly affects men and leads to the ...
(Date:2/28/2015)... Portland, OR (PRWEB) February 28, 2015 ... at the 2015 Japan Architecture & Construction Materials Show, ... They’ll join more than 1,000 suppliers and top manufacturers ... , Reclaimed wood products sourced and manufactured ... facilities have found popularity in Japan at restaurants, hotels, ...
(Date:2/28/2015)... FL (PRWEB) February 28, 2015 ... organization has sponsored visitor health insurance programs for visitors ... years. Most Indian elderly parents traveling to the United ... such as diabetes and blood pressure. These diseases are ... not even list them as medical conditions. There were ...
Breaking Medicine News(10 mins):Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3
... Founder of ... who accelerated her recovery. Lack of friends connected to poorer health Company aims to reduce ... ... The Friendship Stone will mark Friendship Week starting August 2nd. Founder, Cathy Raff, will dedicate ...
... , , New Report Is ... Lower Costs , , KANSAS CITY, Mo., ... marks for communicating effectively and treating them respectfully, according to a new patient experience ... 700 doctors are available at http://kcq i c.org ...
... , , OLYMPIA, ... prescription medications since the launch of the free statewide prescription assistance program. ... was launched in August, 2008. The program has no restrictions to membership, ... fill out. Anyone interested in receiving a free card can visit ...
... , , WARSAW, Ind., July ... independent provider of products to the global orthopaedic device industry and other ... results for the period ending July 4, 2009 before the market opens ... call at 8:00 a.m. ET on Thursday, August 6, 2009. , ...
... , , HOUSTON, July 21 US Oncology, ... on Thursday, August 6, 2009. , , A ... ET following distribution of the earnings release. Additional information will be available on ... on the day of the earnings announcement. , , ...
... IHA Completes the Second Chapter of the ... for Measurement Years 2006 - 2009 , ... (IHA) is pleased to announce the publication of "The Second Chapter," a ... for performance (P4P) program - the largest non-governmental physician incentive program in ...
Cached Medicine News:Health News:The Friendship Stone Helps Friends Remain Healthy 2Health News:The Friendship Stone Helps Friends Remain Healthy 3Health News:The Friendship Stone Helps Friends Remain Healthy 4Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 2Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 3Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 4Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 5Health News:Free Drug Card Has Saved Washington Residents $2.6 Million 2Health News:Symmetry Medical to Report Second Quarter 2009 Financial Results on August 6, 2009 2Health News:US Oncology to Report 2009 Second Quarter Operating Results 2Health News:Integrated Healthcare Association Releases White Paper on Pay for Performance 2
Used with Single Tantalum Clip (E5381 854) and Double Tantalum Clip (E5381 853). Overall length: 7.2 mm....
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
2 mm x 0.75 mm. Overall length: 125 mm, 4.9 inches....
...
Medicine Products: